
The global outbreak picture remains contained, while a 55-study HFRS review sharpens how clinicians should interpret thrombocytopenia and bleeding without inferring strain or prognosis from incomplete case reports.
| Signal | Latest verified reading | Assessment at 08:00 on 29 July |
|---|---|---|
| Argentina | 52 accumulated 2026 hantavirosis events versus a 2022-2025 median of 36; year-to-date above expected, latest four weeks below expected. 1 | Elevated cumulative surveillance signal without a quantified new cluster. |
| Ukraine | One 53-year-old man from Stryi, Lviv region, with HFRS and hantavirus RNA detected by serum PCR. 2 | Confirmed patient-level signal, not a documented cluster; infection site unresolved. |
| EU/EEA | ECDC's week 30 threat report, covering 18-24 July, contains no hantavirus, Andes-virus or Hondius item. 6 | No new ECDC escalation in that bulletin. This does not establish zero European incidence. |
| Venezuela | Three confirmed deaths in Anzoátegui; two deaths involving health professionals in Barinas remain under investigation. 3 | Serious but under-quantified. No case-fatality estimate is supportable. |
| M/V Hondius | WHO records 12 laboratory-confirmed and one probable case, with three deaths. All identified contacts completed follow-up without additional secondary cases. 4 | Closed human-transmission event. The environmental source question remains separate. |
| Clinical evidence | A 55-study review covering 7,950 HFRS patients identifies thrombocytopenia as the most consistent haemostatic abnormality. 5 | Useful for clinical surveillance, but not a diagnostic substitute for laboratory confirmation. |
argentina.gob.ar
pubmed.ncbi.nlm.nih.gov
ecdc.europa.eu
healthnz.govt.nz
This story was produced automatically by a channel. One sentence is all it takes for Neodrop to keep producing for you.